Related references
Note: Only part of the references are listed.Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance
Peter Dietrich et al.
GUT (2018)
IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
Bowie Y. Cheng et al.
CANCER RESEARCH (2018)
Sestrin2 facilitates glutamine-dependent transcription of PGC-1 and survival of liver cancer cells under glucose limitation
Ashish Kumar et al.
FEBS JOURNAL (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma
Daniela Pollutri et al.
CELL DEATH & DISEASE (2018)
Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
Jun Li et al.
CELL DEATH & DISEASE (2018)
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1
Rosalba D'Alessandro et al.
CELLULAR ONCOLOGY (2018)
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
Eroje M. Ahmed et al.
CELLULAR ONCOLOGY (2018)
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
Zuzana Macek Jilkova et al.
Oncotarget (2018)
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma
Sainan Li et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
Lixia Gao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Sestrin2 and sestrin3 suppress NK-92 cell-mediated cytotoxic activity on ovarian cancer cells through AMPK and mTORC1 signaling
Xuejin Wang et al.
ONCOTARGET (2017)
Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis
Jin Shang et al.
ONCOTARGET (2017)
Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation
Alicia Bort et al.
ONCOTARGET (2017)
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
Yuki Haga et al.
PLOS ONE (2017)
Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib
Fiona A. Ross et al.
CELL CHEMICAL BIOLOGY (2017)
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Yan-jing Zhu et al.
ACTA PHARMACOLOGICA SINICA (2017)
SESN2 correlates with advantageous prognosis in hepatocellular carcinoma
Shaosen Chen et al.
DIAGNOSTIC PATHOLOGY (2017)
PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression
Tao Luo et al.
AUTOPHAGY (2016)
Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
Xiaofang Sun et al.
HEPATOLOGY (2016)
Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma
Yuri Cho et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours
Fiona A. Ross et al.
FEBS JOURNAL (2016)
ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α
Fu-Quan Wu et al.
JOURNAL OF HEPATOLOGY (2016)
Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis
Sen Guo et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
Aline Houessinon et al.
MOLECULAR CANCER (2016)
Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient
Eva Dazert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs
D. Grahame Hardie et al.
TRENDS IN CELL BIOLOGY (2016)
AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin
Mei Gao et al.
ONCOTARGET (2016)
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1
Ji-chao Wei et al.
ACTA PHARMACOLOGICA SINICA (2015)
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
Jiang Chen et al.
CANCER LETTERS (2015)
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib
Naoki Ishijima et al.
CANCER SCIENCE (2015)
Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway
Wenqing Tang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer
Wei-Ching Chen et al.
ONCOTARGET (2015)
The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
Valentina Tesori et al.
SCIENTIFIC REPORTS (2015)
BIRC6 promotes hepatocellular carcinogenesis: Interaction of BIRC6 with p53 facilitating p53 degradation
Wenqing Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Sestrin2 Protein Positively Regulates AKT Enzyme Signaling and Survival in Human Squamous Cell Carcinoma and Melanoma Cells
Baozhong Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines
Sunbin Ling et al.
ONCOLOGY REPORTS (2014)
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma
Alex Y. Chang et al.
ANTI-CANCER DRUGS (2013)
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling
Claudia Fumarola et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
Hannah van Malenstein et al.
CANCER LETTERS (2013)
Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death
I. Ben-Sahra et al.
CELL DEATH AND DIFFERENTIATION (2013)
Sestrins Orchestrate Cellular Metabolism to Attenuate Aging
Jun Hee Lee et al.
CELL METABOLISM (2013)
Sestrins Activate Nrf2 by Promoting p62-Dependent Autophagic Degradation of Keap1 and Prevent Oxidative Liver Damage
Soo Han Bae et al.
CELL METABOLISM (2013)
The Noncytotoxic Dose of Sorafenib Sensitizes Bel-7402/5-FU Cells to 5-FU by Down-Regulating 5-FU-Induced Nrf2 Expression
Suna Zhou et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Hypoxia-Mediated Sorafenib Resistance Can Be Overcome by EF24 Through Von Hippel-Lindau Tumor Suppressor-Dependent HIF-1α Inhibition in Hepatocellular Carcinoma
Yingjian Liang et al.
HEPATOLOGY (2013)
The Degree of Liver Injury Determines the Role of p21 in Liver Regeneration and Hepatocarcinogenesis in Mice
Laura Elisa Buitrago-Molina et al.
HEPATOLOGY (2013)
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
Bo Zhai et al.
WORLD JOURNAL OF HEPATOLOGY (2013)
Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
Kuen-Feng Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Mechanisms of acquired resistance to targeted cancer therapies
Mark R. Lackner et al.
FUTURE ONCOLOGY (2012)
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma
Satoshi Shimizu et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
Zakaria Ezzoukhry et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
Justin N. Bottsford-Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
Marie-Jose Blivet-Van Eggelpoel et al.
JOURNAL OF HEPATOLOGY (2012)
Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies
Shubha Bagrodia et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells
Ning Wang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism
Jeng-Fong Chiou et al.
CANCER BIOLOGY & THERAPY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells
Yvonne Will et al.
TOXICOLOGICAL SCIENCES (2008)
Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents
Robert O'Connor et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma
Y Ito et al.
PATHOLOGY RESEARCH AND PRACTICE (2001)
Share Paper
